• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Appeals court shoots down Synthes bid to unseal grand jury records in Norian bone cement trial

Appeals court shoots down Synthes bid to unseal grand jury records in Norian bone cement trial

September 12, 2017 By Brad Perriello

Norian bone cementJohnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes lost its bid to have some rand jury records unsealed for a wrongful death lawsuit brought over its Norian bone cements.

At least 5 patients died during otherwise routine operations after the Norian cement was used off-label in their spine surgeries. The bone cement was initially developed by a company called Norian, which Synthes bought in 1999 for about $50 million. Synthes, in turn, was acquired by J&J for $21.3 billion in 2012.

The FDA approved Norian for use in arm bones and portions of the skull, but in 2007 required Synthes to put a warning label on the product about its contra-indication for spine surgeries. Lawsuits filed by the families of the patients who died allege that Synthes knew as early as 2002 that Norian was unsafe for use in the spine due to its propensity to form clots in the bloodstream.

Synthes paid paid $22.5 million in fines and was forced to sell Norian to settle federal criminal charges that it ran an off-label promotion scheme for the cement. Four Synthes executives – Michael Huggins, Thomas Higgins, John Walsh and Richard Bohner – were sentenced to prison terms after pleading guilty to misdemeanor charges over the scheme. A series of wrongful death lawsuits followed, brought by the families of deceased patients; Synthes settled one of those cases after a jury cleared the doctor and medical center also named as defendants.

In the case of two other patients who died during vertebroplasties in 2003 and 2004, one of the treating surgeons testified during discovery that both a sales rep and an executive from Synthes told him that the Norian cement was FDA-approved for vertebroplasties, according to court documents. Synthes asked the U.S. District Court for Eastern Pennsylvania to unseal some of the grand jury documents in the case and appealed to the U.S. Court of Appeals for the 3rd Circuit after it was denied.

Last week the appeals court denied the Synthes motion in a unanimous decision.

“The interest in secrecy in this case remains great. Synthes is hoping to use grand jury materials to undermine the credibility of Dr. Nottingham, a key witness during the grand jury proceeding, and to impliedly shift blame for the death of his patient to him, away from Synthes. This is precisely the kind of ‘future retribution’ that could chill the candor of future grand jury witnesses. While this need for secrecy is not insurmountable, it has not been overcome in this case,” the 3rd Circuit ruled.

The appeals court also shot down the company’s argument that some of the interviews with Dr. Paul Nottingham that never made it to the grand jury shouldn’t be subject to the grand jury secrecy rule. The higher court also shot down Synthes’s argument that business records, even if presented to a grand jury, are not subject to the secrecy rule because they were created independent of the grand jury probe.

Kensey Nash (NSDQ:KNSY), which paid $22 million for the Norian product line, was later bought up by Dutch firm Royal DSM for $360 million in 2012

Filed Under: Legal News, Orthopedics Tagged With: depuysynthes, Johnson and Johnson, Norian Corp.

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy